Results from a study on bronchoscopic lung volume reduction and lung volume reduction surgery may aid medical professionals in selecting the best treatment for patients with emphysema. A recent study ...

Bronchoscopic lung volume reduction (BLVR) significantly improved lung function in a subset of patients with chronic obstructive pulmonary disease (COPD) with alpha-1 antitrypsin deficiency (AATD), ...

The first randomized controlled trial to compare two different lung volume reduction procedures for people with emphysema has found that both lead to similar improvements in lung function, ...

• Bronchoscopic lung volume reduction (BLVR) done under moderate sedation (MS) may have lower rate of complications especially pneumothorax as compared to what is quoted in literature when procedure ...

At 12 months, the average improvement from baseline on the 10-point BODE index -- the study's primary endpoint -- was a similar -1.10 (SD 1.44) with LVRS and -0.82 (1.61) with BLVR (P=0.54), Sara ...

Emerging bronchoscopic therapies provide minimally invasive options for COPD, filling the gap between traditional and invasive treatments. Bronchoscopic lung volume reduction (BLVR) uses one-way ...

LOS ANGELES—January 26, 2025—As contemporary surgical practice continues to evolve, patients who undergo surgical lung volume reduction (LVRS) for advanced emphysema may survive longer and with fewer ...

Lung volume reduction surgery (LVRS) is a treatment for end-stage lung disease caused by emphysema. Emphysema is a type of chronic obstructive pulmonary disease (COPD) that causes shortness of breath ...

The National Emphysema Treatment Trial (NETT) was a multicenter, randomized, controlled clinical trial comparing the efficacy of lung volume reduction surgery (LVRS) plus medical management with ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Compared with baseline, FEV 1 increased 5 years after ...

REDWOOD CITY, Calif. & BARCELONA, Spain--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announces the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Studies assessing bronchoscopic lung volume reduction ...